ORANGE COUNTY, Calif., May 24, 2012 /PRNewswire/ -- Dr. James Smith, President of NanoSmart Pharmaceuticals, Inc., a California corporation developing a novel drug-delivery platform for cancer pharmaceuticals, announced today that the company has added Dr. Paul Glidden as Vice President of Research and Development.
"Dr. Glidden has worked for over 20 years developing new chemical and molecular entities leading to over a dozen commercialized pharmaceuticals," said Dr. Smith. "His expertise and proven track record will be instrumental in accelerating and expanding NanoSmart's development program," declared Dr. Smith. "We're very pleased to welcome Dr. Glidden to our team."
Dr. Glidden has extensive experience with small molecule and biological therapeutic modalities. As founder, director and VP of Development of BioVascular, Inc., he developed Saratin for the treatment and prevention of intimal hyperplasia, and Anagrelide CR, a novel formulation with improved safety of a small molecule for the treatment of essential thrombycythemia. As VP of Development at Angiosyn, Inc (acquired by Pfizer), he was responsible for all non-clinical, manufacturing, regulatory, quality, and clinical activities for a recombinant protein with anti-angiogenic properties.
"Based on my personal experience with pediatric cancer in my own family, I have a deep interest in developing novel cancer pharmaceutical products that may help the children of other families," explained Dr. Glidden. "NanoSmart's immunoliposomal formulations are designed to more safely deliver the toxic drugs to the target cancer tissues while protecting surrounding healthy tissues. In addition, NanoSmart's platform opens up a multitude of targets using the same delivery system, including a range of rare, pediatric cancers."
Dr. Glidden holds a B.S. degree in Biochemistry and Biophysics from Oregon State University and a Ph.D. in Pharmacology and Toxicology from the University of California, Irvine.
ABOUT NanoSmart(R) Pharmaceuticals, Inc.
NanoSmart(R) Pharmaceuticals, Inc., a private biotechnology company, is developing novel proprietary drug delivery products to treat cancer and other serious life threatening diseases. NanoSmart's patented platform drug delivery system utilizes human autoimmune antibodies that target many different types of cancer and other diseases. NanoSmart has completed development of its preliminary immunoliposomal formulations and is currently engaged in preclinical testing of its lead candidate drug products. This press release may contain forward-looking statements. There can be no assurance that development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.
For more information, visit www.nanosmartpharma.com
SOURCE NanoSmart Pharmaceuticals, Inc.